Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2010 | 2 |
2011 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
Clin Gastroenterol Hepatol. 2010 Jul;8(7):600-9. doi: 10.1016/j.cgh.2010.01.014. Epub 2010 Feb 1.
Clin Gastroenterol Hepatol. 2010.
PMID: 20117244
Clinical Trial.
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.
Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ; PRECiSE 2 Study Investigators.
Schreiber S, et al.
Am J Gastroenterol. 2010 Jul;105(7):1574-82. doi: 10.1038/ajg.2010.78. Epub 2010 Mar 16.
Am J Gastroenterol. 2010.
PMID: 20234346
Clinical Trial.
Item in Clipboard
AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
Gamstätter T, Weinmann A, Schadmand-Fischer S, Spies PR, Niederle IM, Schuchmann M, Galle PR, Wörns MA.
Gamstätter T, et al. Among authors: spies pr.
Onkologie. 2011;34(10):538-42. doi: 10.1159/000332137. Epub 2011 Sep 16.
Onkologie. 2011.
PMID: 21985853
Item in Clipboard
Cite
Cite